AP Biosciences Past Earnings Performance
Past criteria checks 0/6
AP Biosciences's earnings have been declining at an average annual rate of -83.2%, while the Biotechs industry saw earnings growing at 19.8% annually.
Key information
-83.2%
Earnings growth rate
-70.7%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | n/a |
| Return on equity | -25.0% |
| Net Margin | -1,387.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How AP Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 32 | -447 | 58 | 430 |
| 31 Mar 24 | 32 | -393 | 50 | 384 |
| 31 Dec 23 | 32 | -339 | 43 | 337 |
| 30 Sep 23 | 16 | -292 | 40 | 279 |
| 30 Jun 23 | 0 | -244 | 36 | 221 |
| 31 Mar 23 | 0 | -266 | 35 | 242 |
Quality Earnings: 6945 is currently unprofitable.
Growing Profit Margin: 6945 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 6945's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 6945's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6945 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.6%).
Return on Equity
High ROE: 6945 has a negative Return on Equity (-25.05%), as it is currently unprofitable.